Susan Schiff, MD
Internal Medicine · Lakewood, CONPI 1386710424
Payments from drug & device makers
Across 205 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$528
- GSK$450
- AbbVie$448
- AstraZeneca$403
- Astellas Pharma US Inc$268
- Lilly USA, LLC$160
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,42198%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 34 | $528 |
| GSK | 26 | $450 |
| AbbVie(2 entities) | 25 | $448 |
| AstraZeneca | 27 | $403 |
| Astellas Pharma US Inc | 11 | $268 |
| Lilly USA, LLC | 11 | $160 |
| Pfizer | 8 | $158 |
| E.r. Squibb & Sons, L.L.C. | 8 | $155 |
| Johnson & Johnson | 9 | $152 |
| Amgen | 8 | $142 |
| Otsuka America Pharmaceutical, Inc. | 6 | $138 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Amarin Pharma, Inc. | 4 | $67 |
| Amneal Pharmaceuticals LLC | 4 | $60 |
| Bayer | 3 | $57 |
| Merck | 4 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Inogen, Inc. | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Novo Nordisk | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
How this compares
$3,506 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 49 | $74,357 |
| OzempicSemaglutide | 48 | $71,188 |
| EliquisApixaban | 39 | $49,041 |
| XareltoRivaroxaban | 28 | $47,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $39,676 |
| JardianceEmpagliflozin | 25 | $37,195 |
| JanuviaSitagliptin Phosphate | 15 | $28,126 |
| MounjaroTirzepatide | 16 | $27,144 |
| TradjentaLinagliptin | 23 | $21,909 |
| FarxigaDapagliflozin Propanediol | 19 | $21,026 |
| MyrbetriqMirabegron | 20 | $20,516 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,495 |
| SynthroidLevothyroxine Sodium | 32 | $3,806 |
| Levothyroxine Sodium | 294 | $3,501 |
| Esomeprazole Magnesium | 23 | $2,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $160 | $101,50065 claims |
| Novo NordiskOzempic | $13 | $71,18848 claims |
| Boehringer IngelheimJardiance, Tradjenta | $528 | $59,10448 claims |
| PfizerEliquis | $158 | $49,04139 claims |
| Johnson & JohnsonXarelto | $152 | $47,73328 claims |
| GSKTrelegy Ellipta | $450 | $39,67638 claims |
| MerckJanuvia | $55 | $28,12615 claims |
| AstraZenecaFarxiga | $403 | $21,02619 claims |
| Astellas Pharma US IncMyrbetriq | $268 | $20,51620 claims |
| AbbVieSynthroid | $448 | $3,80632 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $3,501294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Lakewood
- Kenneth CohenLakewood$4.5M
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Luke WebbColorado Springs$2.1M
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Steven BrodieColorado Springs$883K
- Monica GrafalsAvon$673K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.